Position Summary

Quotient is seeking an Associate Scientist with experience in molecular biology, immunology and early drug discovery. This position will contribute to the translational validation of discovery platform targets in mechanistic and disease-relevant pharmacological models.

The ideal candidate will be a talented, goal-oriented and highly motivated individual who will play a vital role in progressing the company’s early discovery projects in inflammatory and autoimmune diseases. They will have a strong background in developing complex immune assays with primary human cells and tissues designed to understand the molecular basis of disease states as well as drug mechanism of action. The candidate must be comfortable working in and contributing to a diverse, highly dynamic, fast-paced and cross-functional team environment.

Responsibilities

✓Use insights from literature and experimental results to design, optimize and implement robust in vitro experiments to validate target mechanisms and translational relevance to human disease
✓Execute biochemical and cell-based assays using recombinant proteins, mammalian cell lines and primary cells to define drug mechanism of action
✓Utilize creativity and critical thinking skills to innovate, troubleshoot/optimize experiments and to interpret data to drive go/no go decisions
✓Must display attention to detail, sense of urgency and “outside the box” thinking
✓Work under the supervision of senior members of the team and assist in designing and implementing research protocols
✓Perform laboratory experiments and apply various laboratory techniques including compound screens, flow cytometry, ELISA, qPCR, Western blotting.
✓Conduct in vitro and ex vivo assays, such as but not limited to overexpression, knockdown, knockout on immortalized and primary cells, stimulation, and cytokine profile or functional assays
✓Collect, analyze and interpret scientific data accurately
✓Maintain precise experimental records and documentation
✓Contribute to the preparation of research articles, reports and presentations
✓Follow lab safety procedures and rules to ensure a safe working environment
✓Participate in regular team meetings to discuss progress, challenges, and future plans

Qualifications

Essential

✓BS or MS in Immunology, Biochemistry, Molecular Biology, or a related discipline and 3+ years of industry experience for MS or 5+ years for BS
✓In depth understanding of cellular and molecular biology techniques including mammalian cell culture, transfection, CRISPR, western blots, qPCR, immunofluorescence and flow cytometry
✓Prior experience running cell-based compound screening assays
✓Prior experience in an industrial setting, and familiarity with Good Laboratory Practice (GLP) as well as proficiency in the use of Electronic Laboratory Notebooks (ELN)
✓Experience with experimental design and strong proficiency in assay execution, troubleshooting, data analysis, and data interpretation
✓Outstanding organizational and record keeping skills
✓Execution focused, team oriented, and highly motivated

Desirable

✓Proficiency with RNA-seq, cloning and image analysis
✓Previous experience with lentiviral transductions or AAV transfection/transduction

Values and Behaviors

✓Encourage respectful disagreement and cultivate open-minded, ego-free interactions to continuously push each other towards excellence
✓Seek out diverse perspectives; practice active listening and genuine curiosity to ensure all contributions are valued, regardless of source
✓Recognize the impact of your behavior, language and attitudes, and strive for balanced, meaningful exchanges that enhance mutual growth and understanding in all interactions
✓Use a company-first mindset to guide decision-making; prioritize team over individual success
✓Take calculated risks and challenge convention in the quest for exceptional outcomes

About Quotient

Quotient Therapeutics is a privately-held, early stage company developing breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our work in somatic genomics, we are forging a new status quo for biopharma research and development across a broad pipeline of internal and partnered programs.

The company was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), and Syros Pharmaceuticals (SYRS).

Privacy Notice for Applicants: When you apply for a role at Flagship Pioneering or one of its portfolio companies, we collect and use personal information you provide (such as your name, contact details, work history, and application materials) to evaluate your application, communicate with you, and comply with legal obligations. Your application data is processed through Greenhouse, our applicant tracking system, and may also be reviewed using AI-assisted screening tools. We do not sell your personal information.

California residents have rights under the CCPA/CPRA including to know, delete, and opt out of the sharing of their personal information. If you are located in the EU or UK, we process your data under GDPR and you have rights to access, rectify, and erase your data. To exercise your rights or for questions, contact privacy@flagshippioneering.com.

The salary range for this role is $96,000 - $126,500. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Quotient Therapeutics, Inc. currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits.

Compensation and benefits information is based on Quotient Therapeutics, Inc.'s good faith estimate as of the date of publication and may be modified in the future.